Wealth Enhancement Advisory Services LLC Purchases 11,817 Shares of Eli Lilly and Company $LLY

Wealth Enhancement Advisory Services LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 5.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 213,986 shares of the company’s stock after acquiring an additional 11,817 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Eli Lilly and Company were worth $228,151,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in LLY. Chesapeake Asset Management LLC boosted its stake in Eli Lilly and Company by 3.3% during the 4th quarter. Chesapeake Asset Management LLC now owns 9,158 shares of the company’s stock valued at $9,842,000 after purchasing an additional 290 shares during the period. Peoples Bank KS bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $215,000. Gryphon Financial Partners LLC lifted its holdings in shares of Eli Lilly and Company by 4.5% during the fourth quarter. Gryphon Financial Partners LLC now owns 5,203 shares of the company’s stock worth $5,591,000 after buying an additional 224 shares during the last quarter. Moller Wealth Partners bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $206,000. Finally, Genesis Private Wealth LLC grew its stake in shares of Eli Lilly and Company by 80.6% in the fourth quarter. Genesis Private Wealth LLC now owns 549 shares of the company’s stock worth $590,000 after acquiring an additional 245 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Wolfe Research increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. National Bank Financial set a $1,286.00 price objective on shares of Eli Lilly and Company in a report on Monday, December 1st. Daiwa Securities Group increased their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Argus boosted their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,221.44.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly expanded access for its weight‑loss drug Zepbound by launching a self‑pay option (starting at $299/month for the low dose) through LillyDirect and major pharmacies — a move that should broaden the addressable market and help revenue growth if uptake scales. Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook
• Positive Sentiment: Analysts continue to point to upside after Lilly’s strong February quarter (revenue and EPS beats and raised FY guidance); several pieces highlight upgraded price targets and room for further appreciation based on product momentum. Here’s How Much Upside Eli Lilly Stock Has, According to Analysts
• Neutral Sentiment: Lilly’s leadership joined other U.S. CEOs at the China Development Forum and signaled renewed investment in China; management interest supports long‑term expansion but geopolitical uncertainty keeps execution risk elevated. U.S. executives, from Apple to Eli Lilly, revamp their push into the world’s second-largest economy at the China Development Forum
• Neutral Sentiment: Local planning discussions about a proposed Eli Lilly plant in Lehigh Valley signal capacity expansion plans that could support manufacturing scale — watch for permitting/timeline news that would affect capital expenditure and supply. Lehigh Valley planners to discuss traffic, other potential issues with proposed Eli Lilly plant
• Neutral Sentiment: Market commentary flags an upcoming April 10 event described as a “make‑or‑break” test versus rival Novo Nordisk — this creates short‑term binary risk around competitive positioning in obesity/GLP‑1 markets. Eli Lilly Stock (LLY) Faces This Make-or-Break Test on April 10
• Negative Sentiment: Benzinga and other outlets note the U.S. Supreme Court revived Actos litigation exposure — renewed legal risk could create headline volatility and potential liabilities. What’s Going On With Eli Lilly On Monday?
• Neutral Sentiment: “Should you buy before April 10?” pieces are framing short‑term timing decisions for investors; they reiterate the same balance of strong fundamentals versus near‑term competitive and legal catalysts. Should You Buy Eli Lilly Stock Before April 10?

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $910.59 on Tuesday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock has a fifty day moving average price of $1,019.76 and a two-hundred day moving average price of $960.48. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The firm has a market capitalization of $860.34 billion, a P/E ratio of 39.68, a P/E/G ratio of 1.05 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter in the previous year, the company earned $5.32 EPS. The firm’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.